We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

Diatron (Budapest, Hungary) is exhibiting its advanced hematology analyzers and clinical chemistry analyzers, along with associated reagents at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany. More...

At MEDICA 2022, Diatron is exhibiting the KleeYa open, flexible CLIA platform which provides a unique approach to the use of different bead-based CLIA technologies, offering superior assay performance and providing ease of use with cost containment. Diatron’s KleeYa, a highly flexible, fast and sensitive random access CLIA platform for immunoassay menu, handles tests from various providers and is able to combine a wide variety of assay designs.

Also on display at the Diatron booth at MEDICA is the company’s new P780 clinical chemistry analyzer alongside the Aquila 3-part differential hematology analyzer. The Diatron Aquila is an innovative and revolutionary hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. The Diatron Aquila can be used to perform complete CBC with human blood, collected in either standard EDTA collection tubes (Vacutainer type) or with micro sampling tubes. It delivers accurate results with regular and micro-sampling collection tubes with only 20 μl blood required and results in less than one minute. The QC menu offers the user the opportunity to use secondary QC limits for all parameters providing the extended QC option. The Diatron Aquila featuring the company’s latest technology offers an optimal testing solution for both experienced and inexperienced users and practices that require a high quality hematology analyzer.

Related Links:
Diatron 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.